Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
08:30am, Thursday, 06'th Jun 2024
Company Granted New European Patent for ENHANZE® Drug Delivery Platform SAN DIEGO , June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the Compa
Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
04:05pm, Wednesday, 05'th Jun 2024
Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET SAN DIEGO , June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the grant of Euro
Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
04:30pm, Tuesday, 04'th Jun 2024
SAN DIEGO , June 4, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host inv
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:41am, Friday, 31'st May 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Updated Prescription Drug User Fee Act goal date of December 29, 2024 SAN DIEGO , May 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol M
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
10:45am, Thursday, 16'th May 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The 3 Best Biotech Stocks to Buy in May 2024
06:15am, Thursday, 09'th May 2024
We live in the best of times where life is not capped at 45 or 50 years of age, all thanks to wonderful discoveries in the field of biotechnology. The resources being invested to produce new drugs and
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
11:36am, Wednesday, 08'th May 2024
Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.
Halozyme to Participate in Upcoming Investor Conferences
08:30am, Wednesday, 08'th May 2024
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor
Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript
07:32pm, Tuesday, 07'th May 2024
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications Hel
Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
07:01pm, Tuesday, 07'th May 2024
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall S
Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
06:26pm, Tuesday, 07'th May 2024
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.47 per share a year ago.
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
04:01pm, Tuesday, 07'th May 2024
Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.79 1 Royalty Revenue Increased 21% YOY t
Halozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:22am, Monday, 06'th May 2024
Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed f
